Patient considerations in metastatic colorectal cancer - role of panitumumab.

Onco Targets Ther · 2017 · PMC5391168 · PMID 28435294

Europe PMC DOI

hedged sentences

0.0720

closest p · 1.4× alpha

0.1200

boldest claim

The sentences

did not reach statistical significanceP =0.072so close (0.05 < p ≤ 0.1)

OS favored the panitumumab arm with a 4.2-month improvement for wild-type KRAS patients; however, this did not reach statistical significance (23.9 months compared to 19.7 months, P =0.072).

also in 111,027 other papers

a nonsignificant trendP =0.12not close (p > 0.1)

A nonsignificant trend toward increased OS was observed in the wild-type group (median OS was 14.5 months vs 12.5 months, HR =0.85, 95% CI: 0.70–1.04; P =0.12), and a 35% improvement in the response rate against 10% was observed with the addition of panitumumab.

also in 5,406 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.